Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Leiomyoma 2Ovarian Neoplasms 1Osteoporosis 1Myocardial Ischemia 1Heart Diseases 1Coronary Disease 1Colonic Neoplasms 1Cardiovascular Diseases 1Breast Neoplasms 1Bone Diseases 1

Interventions

relugolix 8ulipristal acetate 7telapristone acetate 7estradiol, norethindrone drug combination 7vilaprisan 6asoprisnil 6Estradiol 5linzagolix 4elagolix 4Norethindrone Acetate 3Leuprolide 3Sugars 2Progestins 2epigallocatechin gallate 1Uterine Myomectomy 1Uterine Artery Embolization 1Tranexamic Acid 1Tea 1Standard of Care 1Sodium Chloride 1Saline Solution 1Misoprostol 1Mifepristone 1Megestrol Acetate 1Medroxyprogesterone Acetate 1Laparoscopy 1Iron 1Hysterectomy 1Goserelin 1Gonadotropin-Releasing Hormone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Leiomyoma × Progestins × Clear all
NCT01156857 2016-01-15

PEARLIII

PregLem SA

Phase 3 Completed
209 enrolled

Leiomyoma

NCT01252069 2016-01-13

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

PregLem SA

Phase 3 Completed
132 enrolled

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡